These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37730962)

  • 1. Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?-Insights from an international population-based study.
    Kridin K; Abdelghaffar M; Mruwat N; Ludwig RJ; Thaçi D
    J Eur Acad Dermatol Venereol; 2024 Feb; 38(2):315-324. PubMed ID: 37730962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors - A population-based study.
    Kridin K; Zirpel H; Mruwat N; Ludwig RJ; Thaci D
    J Eur Acad Dermatol Venereol; 2023 Nov; 37(11):2319-2326. PubMed ID: 37466275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR database.
    Strunz PP; Englbrecht M; Risser LM; Witte T; Froehlich M; Schmalzing M; Gernert M; Schmieder A; Bartz-Bazzanella P; von der Decken C; Karberg K; Gauler G; Wurth P; Späthling-Mestekemper S; Kuhn C; Vorbrüggen W; Heck J; Welcker M; Kleinert S
    Front Immunol; 2024; 15():1395968. PubMed ID: 38846940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS).
    Marcombes C; Penso L; Weill A; Dray-Spira R; Zureik M; Sbidian E
    Br J Dermatol; 2023 Oct; 189(5):561-568. PubMed ID: 37479503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry.
    Lebwohl M; Strober B; Schrader A; Li AH; Eckmann T; Zhu B; Malatestinic WN; Birt J; Feely M; Blauvelt A
    Drugs Real World Outcomes; 2024 Sep; 11(3):451-464. PubMed ID: 38914857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS).
    Pina Vegas L; Hoisnard L; Bastard L; Sbidian E; Claudepierre P
    RMD Open; 2022 Dec; 8(2):. PubMed ID: 36597983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis Registry.
    Lockshin B; Cronin A; Harrison RW; McLean RR; Anatale-Tardiff L; Burge R; Zhu B; Malatestinic WN; Atiya B; Murage MJ; Gallo G; Strober B; Van Voorhees A
    Dermatol Ther; 2021 Mar; 34(2):e14808. PubMed ID: 33491259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network.
    Strunz PP; Englbrecht M; Risser LM; Witte T; Froehlich M; Schmalzing M; Gernert M; Schmieder A; Bartz-Bazzanella P; von der Decken C; Karberg K; Gauler G; Wurth P; Späthling-Mestekemper S; Kuhn C; Vorbrüggen W; Heck J; Welcker M; Kleinert S
    Rheumatol Int; 2024 Oct; 44(10):2057-2066. PubMed ID: 39136784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of COVID-19 infection, hospitalization, and mortality in patients with psoriasis treated by interleukin-17 inhibitors.
    Kridin K; Schonmann Y; Solomon A; Damiani G; Tzur Bitan D; Onn E; Weinstein O; Cohen AD
    J Dermatolog Treat; 2022 Jun; 33(4):2014-2020. PubMed ID: 33759683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Persistence and Adherence Among Patients With Psoriatic Arthritis Who Initiated Targeted Immune Modulators in the US: A Retrospective Cohort Study.
    Walsh JA; Cai Q; Lin I; Pericone CD; Chakravarty SD
    Adv Ther; 2021 May; 38(5):2353-2364. PubMed ID: 33759081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Peripheral Arthritis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations.
    Leung YY; Korotaeva TV; Candia L; Pedersen SJ; Bautista Molano W; Ruderman EM; Bisoendial R; Perez-Alamino R; Olsder W; Möller B; Grazio S; Gudu T; Mody GM; Pineda C; Raffayova H; Rohekar S; Goldenstein-Schainberg C; Gutierrez Urena SR; Casasola Vargas JC; Meghnathi B; Prasad R; Richette P; Miranda JRS; Malliotis N; Lindqvist U; Simon D; Ezeonyeji A; Soriano ER; FitzGerald O
    J Rheumatol; 2023 Jan; 50(1):119-130. PubMed ID: 36243409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proportions of Biologic Discontinuation Among Psoriasis Patients With Metabolic Comorbidities.
    Enos CW; Ramos VL; McLean RR; Lin TC; Foster N; Dube B; Van Voorhees AS
    J Psoriasis Psoriatic Arthritis; 2023 Jan; 8(1):7-10. PubMed ID: 39296950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin-17 Inhibitors: A Nationwide Population-Based Study Using the French National Health Data System.
    Penso L; Bergqvist C; Meyer A; Herlemont P; Weill A; Zureik M; Dray-Spira R; Sbidian E
    Arthritis Rheumatol; 2022 Feb; 74(2):244-252. PubMed ID: 34279061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting the Time to Relapse Following Withdrawal from Different Biologics in Patients with Psoriasis who Responded to Therapy: A 12-Year Multicenter Cohort Study.
    Huang YH; Hung SJ; Lee CN; Wu NL; Hui RC; Tsai TF; Huang CM; Chiu HY
    Am J Clin Dermatol; 2024 Nov; 25(6):997-1008. PubMed ID: 39283586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does previous use of tumour necrosis inhibitors change the therapeutic effect of interleukin (IL)-17 or IL-12/23 inhibitors on psoriasis and psoriatic arthritis? Results of a systematic review.
    Xie Y; Liu Y
    Clin Exp Dermatol; 2022 Sep; 47(9):1627-1635. PubMed ID: 35466472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Systematic Overview of Contraindications and Special Warnings for Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs: Establishing a Framework to Create a "Safety Checklist".
    Skaarup L; Ingrid E; Sepriano A; Nikiphorou E; Østgård R; Lauper K; Grosse-Michaelis I; Kloppenburg M; Glintborg B; Liew DFL; Kragstrup TW
    Drug Saf; 2024 Nov; 47(11):1075-1093. PubMed ID: 39012469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
    Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
    Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry.
    Enos CW; Ramos VL; McLean RR; Lin TC; Foster N; Dube B; Van Voorhees AS
    J Am Acad Dermatol; 2022 Jan; 86(1):68-76. PubMed ID: 34256035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiometabolic multimorbidity is common among patients with psoriasis and is associated with poorer outcomes compared to those without comorbidity.
    Enos CW; Ramos VL; McLean RR; Lin TC; Foster N; Dube B; Van Voorhees AS
    J Dermatolog Treat; 2022 Nov; 33(7):2975-2982. PubMed ID: 35737885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability and comparative effectiveness of TNF, IL-17 and IL-23(p19) inhibitors in psoriatic arthritis: a target trial emulation study.
    Stisen ZR; Nielsen SM; Skougaard M; Mogensen M; Jørgensen TS; Dreyer L; de Wit M; Christensen R; Kristensen LE
    Rheumatology (Oxford); 2024 May; 63(6):1543-1551. PubMed ID: 37713434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.